LAUSR

The clinical efficacy of PD‐1 inhibitors as an adjuvant treatment for Asian melanoma patients has not yet been determined. This retrospective study analyzed the clinical data of 90 Chinese patients with completely resected, stage III cutaneous or acral melanoma who received either adjuvant PD‐1 inhibitor or high‐dose interferon α‐2b (HDI). Anti‐PD‐1 treatment resulted in significantly longer RFS and DMFS than HDI in cutaneous melanoma patients, with hazard ratios (HRs) (anti‐PD‐1 versus HDI) of 0.402 (95% CI, 0.183–0.886) and 0.324 (95%CI, 0.122 to 0.861) for RFS and DMFS, respectively. However, adjuvant anti‐PD‐1 treatment had no advantage over HDI in acral melanoma patients with HRs (anti‐PD‐1 versus HDI) of 1.204 (95% CI, 0.521 to 2.781) and 1.968(95% CI, 0.744–5.209) for RFS and DMFS, respectively. Adjuvant anti‐PD‐1 treatment yielded a significantly better prognosis than HDI in Chinese patients with stage IIIB/C cutaneous melanoma, but a significant difference was not observed in those with acral melanoma.